CTC 96
CTC 96 is an antiviral agent, showing inhibitory effects particularly on herpes viruses and adenoviruses. CTC 96 directly blocks the fusion process between the viral envelope and the cell membrane, preventing the entry of viral nucleic acids and proteins into the cells. CTC 96 can completely block the penetration and intercellular transmission of HSV-1, preventing the synthesis of viral proteins and mRNA. CTC 96 exhibits significant anti-adenovirus activity in rabbit eye models. CTC 96 is also effective against varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV). CTC 96 can be used for broad-spectrum antiviral research.
For research use only. We do not sell to patients.
- CAS No.: 149754-11-0
- Formula: C20H30BrCoN6O2
- Molecular Weight:525.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
CTC 96 (0-50 μg/mL, 1 h) effectively inhibits HSV-1, Varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV) infection in Vero cells[1].
CTC 96 (50 μg/mL, 1 h) specifically blocks the membrane fusion step during which the virus enters the cell and does not interfere with the attachment of HSV-1 virus particles to the surface of Vero cells[1].
CTC 96 (50 μg/mL) effectively blocks the entry of the virus, completely interrupting the release of the viral genome and the subsequent viral gene expression process in Vero cells[1].
CTC 96 (50 μg/mL, 16 h) effectively inhibits the direct transmission of the virus among the already infected Vero cells[1].
CTC-96 (0-250 μg/mL, 1 h) demonstrates virucidal activity against Ad5 in tissue culture with HeLa, A549 and SIRC cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eye adenovirus-induced corneal and conjunctival inflammation model established in New Zealand White rabbits[2]
-
Dosage:25 and 50 μg/mL
-
Administration:Eye drops, 6 or 9 times daily for 14-21 days
-
Result:Significantly alleviated the clinical symptoms of conjunctivitis.
Significantly accelerated the clearance of the virus and shorten the course of the disease.
Chemical Information
-
CAS No. 149754-11-0
-
Molecular Weight 525.33
-
Formula C20H30BrCoN6O2
-
SMILES
CC1=[N]2[Co+3]3(O=C(C)[CH-]1)([N]4=C(NC=C4)C)([N]5=C(NC=C5)C)[N](CC2)=C([CH-]C(C)=O3)C.[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Purity & Documentation
References
[1]. Schwartz JA, Lium EK, Silverstein SJ. Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96. J Virol. 2001 May;75(9):4117-28. [Content Brief]
[2]. Epstein SP, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol. 2006 Jun 5;6:22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)